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Abstract
Background: Primary cardiac angiosarcomas are rare, but they are the most aggressive type of primary cardiac
neoplasms. When patients do present, it is with advanced pulmonary and/or cardiac symptoms. Therefore, many
times the correct diagnosis is not made at the time of initial presentation. These patients have metastatic disease
and the vast majority of these patients die within a few months after diagnosis. Currently the treatment choices are
limited and there are no targeted therapies available.
Case presentation: A 56-year-old male presented with shortness of breath, night sweats, and productive cough for
a month. Workup revealed pericardial effusion and multiple bilateral pulmonary nodules suspicious for metastatic
disease. Transthoracic echocardiogram showed a large pericardial effusion and a large mass in the base of the right
atrium. Results of biopsy of bilateral lung nodules established a diagnosis of primary cardiac angiosarcoma.
Aggressive pulmonary disease caused rapid deterioration; the patient went on hospice and subsequently died.
Whole exome sequencing of the patient’s postmortem tumor revealed a novel KDR (G681R) mutation, and focal
high-level amplification at chromosome 1q encompassing MDM4, a negative regulator of TP53.
Conclusion: Mutations in KDR have been reported previously in angiosarcomas. Previous studies also demonstrated
that KDR mutants with constitutive KDR activation could be inhibited with specific KDR inhibitors in vitro. Thus,
patients harboring activating KDR mutations could be candidates for treatment with KDR-specific inhibitors.
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Background
Primary cardiac tumors are very rare; the reported inci-
dence in most autopsy and surgery series varies from
0.001 to 0.3% [1–3]. Of tumors that arise in the heart,
most are benign and approximately 25% are malignant.
About 95% of the malignant tumors are sarcomas, and
they comprise 10 to 15% of the total primary cardiac
tumors. Sarcomas can develop in any site in the heart,
but angiosarcomas, which account for a third of all
sarcomas, normally originate in the right atrium near
the atrioventricular groove [4, 5].
Initially, there are no noticeable symptoms for patients
with cardiac angiosarcoma. When patients do present they
tend to have locally advanced or metastatic disease. Most
symptoms are related to intracardiac flow obstruction,
pericardial effusion and tamponade, tumor embolism, and
systemic or constitutional symptoms due to metastatic
disease [6–8]. Lung metastases are common at presenta-
tion [4, 9]. Additionally, metastases have been reported in
liver, lymph nodes, bone, adrenal glands, and to a lesser
extent the central nervous system (CNS) and spleen [4, 9].
Due to the late stage at presentation, prognosis for
patients with primary angiosarcoma of the heart is poor;
median overall survival varies from 6 months or less for
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untreated patients to 12 months for patients with incom-
plete tumor resection [6, 10–12]. Tumor often invades
into the adjacent tissues, making complete resection chal-
lenging, if not impossible. In some cases, cardiac trans-
plantation for patients with primary cardiac angiosarcoma
has been reported, albeit with poor outcomes, with most
patients dying from recurrence within 1 year of surgery.
Cardiac transplantation is not currently recommended
even for patients without evidence of metastatic disease
due to lack of survival benefit to patients with transplant-
ation [13–15].
Existing treatment strategies include resection for
non-metastatic disease, chemotherapy, and radiation.
There are limited data showing chemotherapy treatment
algorithms for cardiac angiosarcoma. Currently used
chemotherapies include traditional agents such as pacli-
taxel, docetaxel, and doxorubicin. Angiogenesis inhibi-
tors, drugs that target the growth of endothelial cells,
such as bevacizumab, sunitinib, and sorafenib, have been
used as well. Although some therapies may extend the
lifespan of patients when combined with other modal-
ities [16], none of the traditional chemotherapies or
newer agents have been shown to eradicate microscopic
disease [17–20]. Lack of efficacy in existing treatment
options highlights the need for targeted cancer therapies
for patients with cardiac angiosarcoma.
To date, various studies investigated specific genes
and pathways altered in angiosarcoma. V-Myc Avian
Myelocytomatosis Viral Oncogene Homolog (MYC) amp-
lified tumors are common in radiation-induced and
lymphedema-associated angiosarcomas [21]. Moreover,
Fms Related Tyrosine Kinase 4 (FLT4) and MYC co-
amplification was observed in 25% of secondary angiosar-
comas [22]. Point mutations in V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog (KRAS) oncogene were
found in liver angiosarcoma [23]. In other reports, a pri-
mary skin angiosarcoma and liver angiosarcoma lacked
expression of p16, the product of the Cyclin Dependent
Kinase Inhibitor 2A (CDKN2A) gene [24–26]. A number
of studies found high expression of mutated Tumor pro-
tein P53 (TP53) gene in the tumor cells of angiosarcoma
from various tissues of origin [26–29]. Microarray expres-
sion studies revealed upregulation of a number of
vascular-specific receptor tyrosine kinases, including
Tyrosine Kinase with Immunoglobulin like and EGF Like
Domains 1 (TIE1), Kinase Insert Domain Receptor (KDR),
SNF Related Kinase (SNRK), TEK Receptor Tyrosine Kin-
ase (TEK), and Fms Related Tyrosine Kinase 1 (FLT1) in
angiosarcomas [30]. Further examination of these five
genes by full-sequencing identified 10% of angiosarcoma
patients harbored mutations in the KDR gene [30].
More recently, whole exome sequencing of primary
and secondary angiosarcoma demonstrated mutations
in the endothelial phosphatase, Protein tyrosine
phosphatase, receptor type, B (PTPRB) and Phospholipase
C, gamma 1 (PLCG1), a signal transducer of tyrosine kin-
ase activators [31]. In the current study, we used custom-
designed expanded exome capture to interrogate the
genome of an aggressive primary cardiac angiosarcoma
case using a genome-wide sequencing approach that in-
cluded analysis of the annotated coding exome along with
additional probes that allowed for genome-wide copy num-
ber analysis and the structural analysis of specific regions
of the genome to capture translocations and inversions.
This analysis allowed for a comprehensive assessment of
the genomic landscape of this aggressive angiosarcoma.
Herein we describe the results of whole exome se-
quencing a primary, cardiac angiosarcoma. We found a
novel KDR (G681R) mutation which is a putative ligand-
independent activating mutation. Additionally, we dis-
covered a focal high-level amplification at chromosome
1q encompassing MDM4 p53 binding protein homolog
(MDM4), a negative regulator of TP53. We discuss po-
tential therapeutic therapies which may be effective in
treating patients with tumors containing these muta-
tions/amplifications.
Case presentation
This case was presented previously [32]. Briefly, a 56-
year-old Caucasian male was transferred to our hospital
for possible pericardial window by cardiothoracic sur-
gery after a transthoracic echocardiogram revealed a
large pericardial effusion. A computed tomography scan
of the chest revealed numerous pulmonary nodules sur-
rounded by ground glass densities, along with small
pleural effusions, and moderate to large pericardial effu-
sion. Approximately 1250 ml of fluid was removed by
pericardiocentesis, and the fluid was negative for the
presence of infection or malignancy. Whole body posi-
tron emission tomography scan revealed a large, irregu-
larly shaped, strikingly hypermetabolic cardiac lesion of
probable right atrium origin (Fig. 1a). Moreover, there
were extensive hypermetabolic pulmonary nodules in a
background of ground glass infiltrates (Fig. 1b). A
provisional diagnosis of cardiac sarcoma was made, and
the patient underwent a left video-assisted thoracotomy,
pericardial window and biopsy, and left lower lobe resec-
tion. Tumor cells in the lung nodules were both epithe-
liod and spindle-shaped in appearance. They were
immunoreactive for Cluster of Differentiation (CD)31,
CD34, and Factor VIII-related antigen, findings that
were consistent with an angiosarcoma (Fig. 2). Given the
aggressive nature of this cancer, the patient declined
treatment and proceeded with in-hospital hospice where
he expired on hospital day 19. Postmortem examination
showed a large tumor was present in the right atrium at-
tached just cephalad to the tricuspid valve annulus, an-
teriorly and laterally (Fig. 3). The tumor extended into
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the right atrioventricular sulcus. The right coronary ar-
tery was compressed by the tumor in the right atrioven-
tricular sulcus. The neoplasm extended just slightly into
the right ventricular wall but was not present in the ven-




Immunohistochemical staining was performed on tissue
sections of formalin-fixed, paraffin-embedded (FFPE)
tumor samples using the BenchMarch System (Ventana
Medical Systems, Inc., Tucson, AZ). The following pri-
mary antibodies were used: An anti-CD31 mouse mono-
clonal antibody from Dako North America, Inc.
(Carpinteria, CA; M0823; lot # 00079267; 1:100 dilution),
an anti-CD34 mouse monoclonal antibody from Ventana
Medical Systems, Inc (790-2927; lot # 1327304B; 1:1 dilu-
tion), and a Factor VIII-related antigen rabbit polyclonal
antibody from Cell Marque Corp. (Rocklin, CA; 250A; lot
# 1113210A; 1:100 dilution).
Custom probe design for target enrichment
For this project, we used a set of custom baits (Agilent
Technologies, Inc.; Cat# G9496C). Briefly, components
of the expanded exome included the following probe
groups: original baits from SureSelect Human All Exon
V5, (Agilent Technologies, Inc.; Cat # 5190-6209), cus-
tom baits for select break point regions which can result
in oncogenic fusions (as defined by the COSMIC data-
base v67), and common tumor suppressor transcribed
regions (Additional file 1: Table S1). Additionally, to aid
in copy number alteration analysis, Agilent 44 k human
comparative genomic hybridization (aCGH) probes
(Agilent Technologies, Inc.) were supplemented in the
regions where there was no strategic bait coverage
(Additional file 2: Table S2). Expanded exome resulted
in a custom 55.2 Mbp targeted design.
DNA isolation
Genomic DNA was isolated from frozen blood using the
Qiagen QiaAmp DNA Blood Maxi Kit (Qiagen, Inc.,
Valencia, CA). Specifically, frozen blood (8 ml) was
allowed to equilibrate to room temperature and supple-
mented with 2 ml of PBS. The mixture was then treated
with Qiagen protease. Lysis buffer was added to the mix-
ture and DNA isolation was conducted as written per
the manufacturer’s the protocol. DNA was eluted in
1000 μl of Buffer AE. The purified DNA was quantified
using the Qubit 2.0 Fluorometer (Life Technologies,
Grand Island, NY). Absorbance ratios (260/280 and 260/
230) were obtained using Nanodrop spectrophotometer
(Thermo Fisher Scientific, Inc. Waltham, MA). Tumor
DNA was isolated from FFPE tissue using Qiagen
Fig. 1 Chest PET/CT Scan. a Chest PET/CT scan of the chest revealed abnormal uptake in the right atrium with an SUV of 14.9. b Chest PET/CT
scan showed ground glass appearance and uptake indicative of nodules and pleural effusions in lungs; maximal SUVs of lung nodules were 9.0
Zhrebker et al. BMC Cancer  (2017) 17:17 Page 3 of 10
AllPrep DNA/RNA FFPE Kit (Qiagen). Briefly, slides
with 5–10 μM thick FFPE sections were scraped into
microcentrifuge tubes (two total) and treated with
640 μl of Qiagen Deparaffinization Solution. The result-
ing pellets were dried for 10 min at 37 °C and resus-
pended in 150 μl of Buffer PKD containing 10 μl
proteinase K. After 15 min incubation at 56 °C, samples
were cooled on ice for 3 min and then centrifuged at
20,000 x g for 15 min. Genomic DNA was isolated from
the pellets according to manufacturer’s instructions that
included the optional RNAse treatment. Genomic DNA
was eluted with 200 μl of buffer ATE and quantified using
the Qubit 2.0 Fluorometer (Life Technologies) and Nano-
drop spectrophotometer (Thermo Fisher Scientific, Inc.).
Whole exome library construction and target enrichment
Genomic DNA (500 ng) was sheared in 50 μl of TE low
EDTA buffer employing the Covaris E210 system
Fig. 2 Images of the tumor from the lung. a-d Hematoxyalin and eosin-stained tumor sections from lung nodules. a Low power magnification
(40X) of tumor demonstrated nodules of tumor cells can be seen in a background of abundant, fresh blood cells. b Medium power magnification
(100X) showed the tumor cells are both epitheliod and spindle-shaped in appearance. The epitheliod morphology predominates in this area of
the tumor. c High power magnification (400X) illustrated the tumor cells have prominent nucleoli. A mitotic figure can be seen in the center of
the image confirming the tumor is mitotically active. d Another view of the tumor showing both epitheliod and spindle-shaped tumor cells, but
in this section the spindle-shaped cells predominant (40X). e Tumor cells stained positive for CD34, a vascular marker (40X). f Tumor cells showed intense
signal for CD31, another vascular marker (40X). g Factor VIII-related antigen, another endothelial marker commonly used to identify vascular tumors,
demonstrated positivity in the tumor cells (40X)
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(Covaris, Inc., Woburn, MA) to target fragment sizes of
150–200 bp. Fragmented DNA was then converted to an
adapter-ligated whole genome library using the Kapa
On-bead Library Prep kit (Kapa Biosciences, Inc.,
Wilmington, MA; Cat# KK8232) according to the manu-
facturer’s protocol. SureSelect XT Adaptor Oligo Mix
was utilized in the ligation step (Agilent Technologies,
Inc.; Cat# 5190-3619). Pre-capture libraries were ampli-
fied using SureSelect XT primers (Cat# 5190-3620 and
Cat# 5972-3694) for nine cycles. Amplified products
were quantified and quality tested using Qubit® dsDNA
BR Assay Kit (Life Technologies) and the Bioanalyzer
DNA 1000 chip (Agilent Technologies, Inc.). Libraries
were then hybridized to a custom Agilent SureSelect bait
library (custom content regions are provided in
Additional file 1: Table S1). Hybridization reactions were
set up with 750 ng of the adapted library according to the
SureSelect XT protocol with 24 h incubation at 65 °C
followed by post-hybridization washes. SureSelect XT in-
dexes were added to the individual libraries during the
eight-cycle post-capture amplification step. Final captures
were quantified and quality tested using Qubit® dsDNA
HS Assay Kit (Life Technologies) and Bioanalyzer DNA
HS chip (Agilent Technologies, Inc).
Whole exome sequencing and analysis
The sequencing pool was created by evenly combining
four uniquely indexed captures into one pool which was
sequenced across three lanes on Illumina HiSeq 2500 high
output mode at 14 pM clustering density using paired-end
reads (Illumina, Inc.). All sequencing reads were converted
to industry standard FASTQ files using the Bcl Conver-
sion and Demultiplexing tool (Illumina, Inc). Sequencing
reads were aligned to the GRCh37 reference genome
using the MEM module of Burrows-Wheeler Aligner
(BWA) v0.7.8 [33] and SAMTOOLS v0.1.19 [33] to pro-
duce BAM files. After alignment, the base quality scores
were recalibrated and joint small insertions and deletions
(INDEL) realignment was performed on the BAM files
using GATK v3.1-1 [34]. Duplicate read pairs were
marked using PICARD v1.111 [35]. Final BAM files were
then used to identify germline and somatic events.
Germline SNP and INDELS were identified using GATK
haplotype caller in the constitutional sample.
Somatic single nucleotide variations (SNVs) and
INDELs were identified using SEURAT somatic variant
caller [36]. Somatic copy number detection was based
on a log2 comparison of normalized physical coverage
(or clonal coverage) across tumor and normal whole
exome sequencing data, where physical coverage was
calculated by considering the entire region a paired-end
fragment span. Normal and tumor physical coverage was
then normalized, smoothed and filtered for highly repeti-
tive regions prior to calculating the log2 comparison.
Loss of Heterozygosity (LOH) is also deduced by
calculating alternate allele frequencies for SNPs. Briefly,
B-allele frequencies (BAF) are allele fraction of non-
reference reads in the tumor at heterzogote common
polymorphic SNPs (minor allele frequency >5%) from
1000 genomes [37] in the patient’s germline. Only
heterozygous SNPs are plotted determined from that pa-
tient’s germline calls. We use the calculation alt/(ref +
alt) where alt is B. This should be 50/50 unless loss of
heterozygosity (LOH) or allele imbalance has occurred
at that site. The BAF can then be plotted against map
position to identify regions of LOH. Copy number
analysis was also performed using the circular binary
segmentation algorithm DNA copy within the BioCon-
ductor package [38]. Translocation detection was based
on discordant read evidence in the tumor exome se-
quencing data compared to its corresponding normal
data. In order for the structural variant to be called there
needs to be greater than 7 read pairs mapping to both
sides of the breakpoint [37]. Somatic structural rear-
rangements were identified through discordant read
pairs using a previously published algorithm [39].
Fig. 3 Cardiac angiosarcoma the right atrium. The tumor was
approximately 4 cm in diameter and attached just above the
tricuspid valve annulus, extending anteriorly and laterally. The tumor
extended into the right atrioventricular sulcus and was present
throughout the atrioventricular sulcus shortly after the origin of the
right coronary artery and extending posteriorly. For more gross
images see Podduturi and Guileyardo [32]
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Annotation of somatic data
Somatic events are annotated using SNPeff (http://
snpeff.sourceforge.net/), providing basic map position
information as well as additional annotation fields for
mutations and copy number events. For mutations, we
use several functional prediction tools to help prioritize
variants that might confer detrimental functional conse-
quences. We use Mutation Assessor [40], Mutation
Taster2 [41], and PolyPhen-2 [42]. Mutation Assessor
uses a multiple sequence alignment (MSA), partitioned
to reflect functional specificity, and generates conserva-
tion scores for each column to represent the functional
impact of a missense variant [40]. A conservation score
is combined with a specificity score to determine a func-
tional impact score. Variants classed as ‘neutral’ or ‘low’
are predicted to not impact protein function, whereas
variants classed as ‘medium’ or ‘high’ are predicted to re-
sult in altered function. Mutation Taster2 uses Bayesian
classification and evolutionary conservation models to
determine if a variant is likely neutral or deleterious
[41]. PolyPhen-2 uses high-quality multiple protein se-
quence alignment and machine-learning classification to
predict the impact of sequence variants (Benign, Prob-
able Deleterious, or Deleterious) on the stability and
function of a protein using structural and comparative
evolutionary considerations [42].
Results
Somatic alterations in primary cardiac angiosarcoma
We performed next generation sequencing on tumor
and germline DNA from a 56-year old male patient with
diagnosed primary cardiac angiosarcoma using a 55.2
Mbp custom whole exome capture kit. Sequencing sta-
tistics are provided in Additional file 1: Table S1. On-
target coverages of 282X for the tumor and 394X for the
germline were achieved. Importantly, the tumor sample
was FFPE and the blood was fresh. However quality se-
quencing data was generated from both samples evident
by sequencing statistics. Importantly, we generated more
sequencing reads from the tumor sample, but fewer of
these sequencing reads aligned to the exome target re-
gions as there were likely more low quality reads gener-
ated from this FFPE sample (Additional file 1: Table S1).
Variant detection algorithms take into account read and
base quality to help ensure accuracy in allele determination.
This can also have effects on copy number analysis as well.
A measure of the noise in log2(tumor/normal) copy number
comparison or essentially log2(FFPE/Fresh) is the derivative
log2ratio spread or DLR Spread (DLRS). The DLRS statistic
describes the absolute value of the log2 ratio variance from
each probe to the next, averaged over the entire genome
[43]. It is a common measure of noise for CGH arrays [43].
We can also calculate DLRS for copy number from Next
Generation Sequencing data using the same algorithm using
coverage ratios rather than microarray probe intensities. We
can use a similar DLRS threshold as CGH arrays for data of
quality enough to make accurate copy number calls, where
a DLRS of <0.3 represents low enough noise to make accur-
ate gain and deletion calls. In our hands, copy number from
fresh blood normal DNA and fresh tumor DNA typically av-
erages DLRS <0.15, indicative of high quality data. The fresh
blood sample and FFPE sample used in our study has a
DLRS of 0.168 using the copy number tool, supporting high
quality copy number analysis for our samples.
An overview of the tumor genome is provided in the
form of a Circos plot (Fig. 4). Using SEURAT variant
caller, we identified 57 somatic coding SNVs in this pa-
tient’s tumor DNA (Additional file 1: Table S1). Recur-
rent PTPRB and PLCG1 mutations have been previously
reported in this tumor type [31]; however, no somatic
coding mutations affecting either gene were found in
our data set. Annotations of mutations were provided
through SNPeff using several functional prediction algo-
rithms including Mutation Assessor [40], Mutation
Taster2 [41], and PolyPhen-2 [42]. Somatic mutations
classified as medium or high by Mutation Assessor,
Deleterious by MutationTaster2 and Polyphen2 were pri-
oritized (Additional file 1: Table S1). Of note was the
presence of a KDR mutation at position G681R mapping
to the Immunoglobulin (Su(var)3–9, Enhancer-of-zeste,
Trithorax (I-SET) protein domain (Fig. 4; Additional file
2: Table S2). Mutations in KDR that result in constitu-
tive activation of the Vascular Endothelial Growth Factor
Receptor 2 (VEGFR2) receptor leading to induction of
angiogenesis signaling have been reported previously for
other angiosarcoma tumors [30]. This KDR G681R mu-
tation in the KDR gene to be damaging by all prediction
algorithms, however the true functional consequences of
this mutation are unknown. Another mutation predicted
to be damaging by all three prediction algorithms was
Cullin 3 (CUL3) R247Q (Additional file 1: Table S1).
CUL3 encodes cullin 3, a core component of the mul-
tiple cullin-RING-based BCR (BTB- CUL3-RBX1) E3
ubiquitin-protein ligase complexes which mediate the
ubiquitination and subsequent proteasomal degradation
of target proteins [44]. It is involved in Aurora Kinase
and cell cycle control of G1/S checkpoint [45].
Custom probe tiling in our targeted assay allowed for
even genome-wide copy number analysis. We detected
whole chromosome gains of chromosomes 2, 4, 8 and 11
(Fig. 4). This tumor also displayed a low level broad gain
that spanned chromosome (chr)17q12-qter. More focal
events were detected at 1q, 8p and Xq (Fig. 4; Additional
file 3: Figure S1). A focal gain was observed at chrXq28 that
included a number of cancer testis antigens including
Melanoma Antigen Family members (MAGE) -A1, -A2,
-A3, -A4, -A6, -A10, -A12, -2B, CTAG1A and CTAG2. The
chr1 event was characterized by an allele shift and several
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focal regions of amplification spanning an approximate
7 Mb region at 1q32 (Additional file 2: Table S2 and
Additional file 4: Figure S2). Regions of amplification
at this locus encompassed a number of cancer-related
genes including MDM4, Mitogen-Activated Protein
Kinase-Activated Protein Kinase 2 (MAPKAPK2), and
Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic
Subunit Type 2 Beta (PIK3C2B) and several interleukin
genes including IL10, IL19, IL20, and IL24 (Additional file
2: Table S2). The event at chr8p was also characterized by
an allele shift and several focal regions of amplification
and spanned an approximate 5 M region at 8p23
(Additional file 2: Table S2 and Additional file 5: Figure S3).
This region encompassed tankyrase 1 gene, TNKS, which
acts is an activator of the Wingless-Int (Wnt) signaling
pathway [46]. It also contains the GATA Binding Protein 4
(GATA4) gene, which has highest expression in heart tissue
and promotes cardiac myocyte enlargement [47]. Other sig-
nificantly amplified genes found at the 8p23 locus included
Ubiquitin Specific Peptidase 17-Like Family Member 2
(USP17L2), Cathepsin B (CTSB), and Epithelial Splicing
Regulatory Protein 1 (ESPR1) (Additional file 2: Table S2).
Conclusions
In this report we characterized the genomic landscape of
a rare primary cardiac angiosarcoma tumor taken post-
mortem from a 56 year old male patient. We have iden-
tified a number of somatic copy number events, mostly
Fig. 4 Circos plot with whole exome sequencing summary. Copy number alterations (inside track, red = amplifications, green = deletions), Select
somatic SNVs (outside track, blue) and structural events (purple lines)
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marked by amplifications, and SNV alterations in this
patient’s tumor. Our approach did not uncover any
translocations that could result in oncogenic fusions pre-
viously reported in primary angiosarcomas [48, 49].
Copy number coupled with the translocation analysis
suggested a presence of a circular chromosome harbor-
ing the MDM4 gene. We were able to confirm our hy-
pothesis by in silico reconstructing the discordant read
pairs mapping to multiple regions on chr1 and chr8.
Double minute chromosomes and homogeneously
stained regions have been identified in several tumor
types and are biologically complex extrachromosomal
entities frequently harboring known oncogenes (i.e
MYC) and/or oncogenic fusions [50]. Their origin in the
nucleus is quite intriguing and is thought to arise as a
result of several mechanisms including chromothripsis, a
multi-step product of complex duplications and recom-
binations through non-homologous end joining. To our
knowledge, there are no previous reports describing cir-
cular extrachromosomal DNA in primary angiosarcomas
or angiosarcomas of the heart carrying MDM4 gene. Fu-
ture studies investigating frequency of this occurrence in
primary cardiac angiosarcomas could add clinical value.
Another amplified region in this tumor genome mapped
to chrXq28. This locus encompasses the MAGE gene
cluster. Genes belonging to this cluster, cancer testis anti-
gens (CTAs), often exhibit tumor-specific expression and
are currently explored as immunotherapeutic targets in
sarcomas [51], other solid tumors and hematologic malig-
nancies [52]. Several ongoing preclinical and phase I trials
are investigating vaccination-induced immunotherapeutic
response in sarcoma patients with advanced disease
(NCT02054104, NCT01313429, and NCT013441496).
Interestingly, a recent report describes an association be-
tween MAGE-A and MDM2 oncogene, E3 ubiquitin pro-
tein ligase (MDM2)/MDM4 complex in vitro in a human
cell line model [53]. Specifically, MAGE-A was shown to
compete with MDM4 for binding to MDM2 leading to ele-
vated levels of free MDM4. Additionally, the group showed
a positive correlation between MAGE-A and MDM4 by im-
munohistochemistry in primary breast cancer. Although we
cannot comment on expression or protein levels of either
MDM4 or MAGE in this patient’s tumor, the co-
amplification significance of multiple MAGE genes and
MDM4 may merit further exploration in this tumor type.
Recently, another patient presented to our clinic with
a cardiac angiosarcoma and a Foundation One genetic
profile was performed on his tumor. A mutation of un-
known significance in KDR was observed (N704del) in a
region where other mutations, deletions, and insertions
have been reported [54], including the patient described
in the present study. Additionally, amplification of
MDM4 was found as was seen in our initial patient.
Thus, from a potential therapeutic viewpoint one could
one take away several points from these whole exome
sequencing results (fully realizing this is from only two
patients). Firstly, the KDR-G681R mutation, which oc-
curs within the second I-SET domain of this protein, is
novel. The G681 amino acid is highly conserved
throughout evolution suggesting that it is a functionally
relevant residue and based on prediction algorithms is
potentially functionally relevant, however this would
need to be validated through in vitro and/or in vivo cell-
based mechanistic approaches. Although the true func-
tional relevance of the mutation is currently unknown,
this mutation would confer the strongest therapeutic tar-
geting potential. One could consider a vascular endothe-
lial growth factor receptor directed therapy such as
bevacizumab, pazopanib, cabozantinib, vandetanib, ziv-
aflibercept, or ramucirumab. Of note is that sorafenib
and sunitnib inihibited KDR activity in vitro as previ-
ously noted by Antonescu and colleagues [30]. Secondly,
there was high level focal amplification at 1q32, which
contains the MDM4 gene. Although there are multiple
anticancer agents under clinical development which in-
hibit the structurally similar p53 binding protein MDM2
(e.g., the Nutlins etc.) there have not been any under de-
velopment which inhibits MDM4 or MDMX (any MDM
protein). But that has changed with the ongoing devel-
opment of the agent ALRN-6924 an MDM2/MDMX
dual inhibitor (which reactivates p53) [55]. That agent
would be a potential match against the amplified MDM4
target. Although we have provided a relatively high reso-
lution view of the genomic landscape of this tumor, fur-
ther studies are needed to determine the effect of
candidate cancer genes hypothesized from our analysis,
and clinical validation of the frequency of these events
in cardiac angiosarcomas.
Additional files
Additional file 1: Table S1. List of coordinates and genomic regions
submitted to Sure Design software for custom bait selection. (DOCX 18 kb)
Additional file 2: Table S2. Basic Next Generation Sequencing Whole
Exome Alignment Statistics. (DOCX 13 kb)
Additional file 3: Figure S1. Genome-wide chromosomal copy number
plot outputs from 1A) copy number analysis, 1B) LOH and allelic imbalance
analysis, 1C) segmentation algorithm copy number analysis, and 1D)
ExomeCNV copy number analysis. 1A) chromosomal plots contain
chromosomal map position in megabases on the X-axis, and the log2 fold
change ratio information on the Y-axis. Regions of copy neutrality (ratios be-
tween log2FC -0.75 and +0.75) are black, regions of copy number gain (ratio >
log2FC 0.75) are red, and regions of copy number loss (ratios < log2FC -0.75)
are green. 1B) chromosomal plots contain chromosomal map position in
megabases on the X-axis, and the B-allele frequency (BAF) on the
Y-axis revealing chromosomal allelic imbalances. 1C) the copy number log2
fold change ratios (Y-axis) for each chromosome are colored alternately in
green and black across the entirety of the genome map positions along the
X-axis. 1D) chromosomal plots contain chromosomal map position in
megabases on the X-axis, and the log2 fold change ratio information on the
Y-axis derived from ExomeCNV. (ZIP 7726 kb)
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Additional file 4: Figure S2. Chromosome 1 copy number plot
outputs illustrating 1q32 amplification. Plots represent outputs from (2A
upper panel) LOH and allelic imbalance analysis, and (2A lower panel)
copy number analysis. 2A upper panel, chromosome 1 plot with map
position in megabases on the X-axis, and the B-allele frequency (BAF) on
the Y-axis revealing chromosomal allelic imbalances. 2A lower panel,
chromosome 1 plot with map position in megabases on the X-axis, and
the log2 fold change ratio information on the Y-axis. 2B shows 10
megabase zoomed region of chromosome 1 (1q32) amplicon. 2B upper
panel, chromosome 1 zoomed in plot with map position in megabases
on the X-axis, and the B-allele frequency (BAF) on the Y-axis revealing
chromosomal allelic imbalance at this region. 2B lower panel, chromosome
1 zoomed in plot with map position in megabases on the X-axis, and the log2
fold change ratio information on the Y-axis. The map postion related to the
MDM4 gene locus is depicted as a purple line on each plot. (ZIP 1288 kb)
Additional file 5: Figure S3. Chromosome 8 copy number plot
outputs illustrating 8p allelic imbalance and 8p23 amplification. Plots
represent outputs from (upper panel) custom algorithm providing
information on allelic imbalances, and (lower panel) copy number
analysis. Upper panel, chromosome 8 plot with map position in
megabases on the X-axis, and the B-allele frequency (BAF) on the Y-axis
revealing chromosomal allelic imbalances. Lower panel, chromosome 8
plot with map position in megabases on the X-axis, and the log2 fold
change ratio information on the Y-axis. (JPG 1099 kb)
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